Advertisements


Roche"s Immunotherapy Drug Extended Patients" Lives

R.....»»

Category: smallbizSource: wsjDec 7th, 2017

Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients.....»»

Category: topSource: business-standardDec 7th, 2017

Why this doctor returned to Genentech to give hemophilia patients a shot

Dr. Gallia Levy saw the early clinical data around a potential hemophilia A drug that Roche affiliate Chugai Pharmaceutical had developed. Now it was coming to Genentech, and Levy wanted to be there, too......»»

Category: topSource: bizjournalsNov 21st, 2017

Roche win boosts case for adding chemo to cancer immunotherapy

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients.....»»

Category: topSource: business-standardNov 20th, 2017

A rush for immunotherapy cancer drugs means new bedfellows

THE modern pharmaceutical firm lives or dies on the strength of its drug portfolio. As patents expire on lucrative medicines, they must replace the income that has been lost by inventing new drugs, or buying them in from outside. Both paths are expen.....»»

Category: topSource: economistAug 3rd, 2017

A doctor who watched a young White House aide be destroyed by MS 40 years ago now has an approved drug to treat it (RHHBY)

Roche via YouTubeForty years ago, one of Dr. Stephen Hauser’s first patients was a young Harvard Law School graduate and Whit.....»»

Category: topSource: businessinsiderMar 29th, 2017

Here"s What Analysts Are Asking Puma Biotech Following Roche"s Positive Perjeta Results

RBC Capital says the commercial opportunity for Puma Biotechnology Inc (NASDAQ: PBYI)’s breast cancer drug neratinib in the extended adjuvant setting should be “considered as eliminated,” given Roche .....»»

Category: blogSource: benzingaMar 2nd, 2017

Northwestern to co-lead immunotherapy drug trial for rare cancers

In recent years, doctors and patients increas.....»»

Category: topSource: chicagotribuneJan 18th, 2017

Roche Gets Priority Review for Immunotherapy Drug Tecentriq

Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the .....»»

Category: topSource: zacksJan 10th, 2017

Roche (RHHBY) MS Drug FDA Review Date Extended in U.S.

Zacks.....»»

Category: topSource: redinewsDec 22nd, 2016

Roche (RHHBY) MS Drug FDA Review Date Extended in U.S.

Roche (RHHBY) announced that the FDA has extended the PDUFA date for the review of the company's Biologics License Application (BLA) for Ocrevus. .....»»

Category: topSource: zacksDec 21st, 2016

Roche/AbbVie"s Leukemia Drug Venclyxto Gains EU Approval

Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia. Roche Holding AG RHHBY and partner AbbVie Inc. ABBV announced that the European Commis.....»»

Category: topSource: zacksDec 12th, 2016

Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda

Individual lung cancer patients may soon be able to benefit from Keytruda, an immunotherapy drug from Merck & Co., Inc. (NYSE:MRK). The news comes after the confirmation by the New Jersey drug maker that it had gained a second priority review tag from th.....»»

Category: topSource: insidermonkeyDec 2nd, 2016

Amgen shares tick higher on positive migraine drug study

Amgen Inc. shares rose in the extended session Wednesday after the biotech said a late-stage migraine drug study reached its primary endpoint. Amgen shares rose 1.2% to $148.97 after hours. The company said patients given its drug erenumab experienced mi.....»»

Category: topSource: marketwatchNov 16th, 2016

Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment

Merck & Co.’s immunotherapy cancer drug Keytruda received U.S. Food and Drug Administration approval as a first-line treatment for certain lung cancer patients......»»

Category: smallbizSource: wsjOct 24th, 2016

A drug that uses the immune system to fight cancer cells just got approved for lung cancer (RHHBY, BMY, MRK)

Thomson Reuters(Reuters) - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this.....»»

Category: topSource: businessinsiderOct 19th, 2016

FDA Approves Genentech"s Lung Cancer Drug

Roche Group's Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer......»»

Category: topSource: foxnewsOct 18th, 2016

FDA approves Genentech"s lung cancer drug

Roche Group's Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer. Tecentriq may treat lung cancer by working with the immune system and targetin.....»»

Category: topSource: marketwatchOct 18th, 2016

A new kind of drug is working better than chemotherapy in some lung cancer patients (BMY, MRK)

For people with advanced forms of lung cancer, chemotherapy might not be the only — or even the best — option.  The drug, marketed as Keytruda, is one of a new set of drugs called immunotherapy. The drug targets the programmed cell death .....»»

Category: topSource: businessinsiderOct 10th, 2016

Bristol"s Opdivo Disappoints in Lung Cancer, Losing Ground To Rival Merck

FindTheCompany | Graphiq Shares of Bristol-Myers Squibb have fallen 26% since August, when a large study of lung cancer patients failed to demonstrate that its breakthrough cancer drug, Opdivo, could slow tumor growth or extend patients’ lives better th.....»»

Category: topSource: forbesOct 9th, 2016